Medicare Enrolled

Dr. Deirdre Reid-Fighera, M.D.

Rheumatology · Meadowbrook, PA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
1650 HUNTINGDON PIKE, Meadowbrook, PA 19046
2675712151
In practice since 2006 (20 years)
NPI: 1841220662 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Reid-Fighera from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reid-Fighera? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Reid-Fighera

Dr. Deirdre Reid-Fighera is a rheumatology specialist in Meadowbrook, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Reid-Fighera performed 20,818 Medicare services across 906 unique beneficiaries.

Between the years covered by Open Payments, Dr. Reid-Fighera received a total of $2,330 from 23 pharmaceutical and/or device companies across 152 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Reid-Fighera is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 30% volume in PA $2,330 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,818
Medicare services
Top 30% in PA for rheumatology
906
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,041 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
7,950 $34 $70
Denosumab injection (Prolia/Xgeva) 6,240 $18 $25
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
4,790 $25 $105
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
345 $12 $100
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
343 $97 $165
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
179 $55 $150
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
176 $110 $325
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
144 $66 $120
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
130 $6 $50
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
126 $23 $80
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
85 $57 $116
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
78 $134 $195
Injection, methylprednisolone acetate, 40 mg 63 $5 $10
New patient office visit, complex (60-74 min) 35 $164 $275
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
31 $8 $20
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
30 $120 $250
Methylprednisolone acetate injection, 20 mg
A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered.
20 $4 $7
Joint fluid aspiration or injection, medium joint
Removal of fluid from a medium-sized joint or injection of medication into the joint space.
18 $45 $97
Prolonged office E/M service, first 15 minutes
This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service.
18 $27 $50
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
17 $87 $170
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
62.9% high complexity
33.9% medium
3.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$2,330
Total received (2018-2024)
Avg $333/year across 7 years
Bottom 48% in PA for rheumatology
23
Companies
152
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,292 (98.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$38 (1.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$209
2023
$256
2022
$345
2021
$48
2020
$186
2019
$717
2018
$570

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$73
Amgen Inc.
$61
Janssen Biotech, Inc.
$40
UCB, Inc.
$18
Sandoz Inc.
$17
Top 3 companies account for 83.2% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$514
Janssen Biotech, Inc.
$378
Novartis Pharmaceuticals Corporation
$223
Genentech USA, Inc.
$143
UCB, Inc.
$129
Flexion Therapeutics, Inc.
$126
PFIZER INC.
$124
GENZYME CORPORATION
$103
Lilly USA, LLC
$89
AbbVie, Inc.
$81
AstraZeneca Pharmaceuticals LP
$76
GlaxoSmithKline, LLC.
$61
Radius Health, Inc.
$54
ABBVIE INC.
$48
Merck Sharp & Dohme Corporation
$37
Sobi, Inc
$25
AbbVie Inc.
$24
Horizon Therapeutics plc
$20
Aurinia Pharma U.S., Inc.
$20
Sandoz Inc.
$17
Ultragenyx Pharmaceutical Inc.
$16
Hikma Pharmaceuticals USA
$12
Celgene Corporation
$11
Top 3 companies account for 47.8% of all-time payments
Associated products mentioned in payments ›
Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · Cryvista · EVENITY · Enbrel · FORTEO · HYRIMOZ · Humira · ILARIS · KEVZARA · Kineret · LUPKYNIS · Mitigare · Otezla · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TREMFYA · Tavneos · Tymlos · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Meadowbrook?
Compare rheumatologists in the Meadowbrook area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
183
Per 100K population
21.2
County median income
$111,521
Nearest hospital
HOLY REDEEMER HOSPITAL AND MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Reid-Fighera is a mixed practice specialist, with above-average Medicare volume (top 30% in PA), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Reid-Fighera experienced with abatacept infusion (orencia)?
Based on Medicare claims data, Dr. Reid-Fighera performed 7,950 abatacept infusion (orencia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reid-Fighera receive payments from pharmaceutical companies?
Yes. Dr. Reid-Fighera received a total of $2,330 from 23 companies across 152 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reid-Fighera's costs compare to other rheumatologists in Meadowbrook?
Dr. Reid-Fighera's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reid-Fighera) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →